De Novo Design of Drug-Like Molecules by a Fragment-Based Molecular Evolutionary Approach

This paper describes a similarity-driven simple evolutionary approach to producing candidate molecules of new drugs. The aim of the method is to explore the candidates that are structurally similar to the reference molecule and yet somewhat different in not only peripheral chains but also their scaffolds. The method employs a known active molecule of our interest as a reference molecule which is used to navigate a huge chemical space. The reference molecule is also used to obtain seed fragments. An initial set of individual structures is prepared with the seed fragments and additional fragments using several connection rules. The fragment library is preferably prepared from a collection of known molecules related to the target of the reference molecule. Every fragment of the library can be used for fragment-based mutation. All the fragments are categorized into three classes; rings, linkers, and side chains. New individuals are produced by the crossover and the fragment-based mutation with the fragment library. Computer experiments with our own fragment library prepared from GPCR SARfari verified the feasibility of our approach to drug discovery.

[1]  Akiko Itai,et al.  Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation , 1991 .

[2]  Valerie J. Gillet,et al.  SPROUT: A program for structure generation , 1993, J. Comput. Aided Mol. Des..

[3]  Johann Gasteiger,et al.  A Graph-Based Genetic Algorithm and Its Application to the Multiobjective Evolution of Median Molecules , 2004, J. Chem. Inf. Model..

[4]  Yoshimasa Takahashi.  Chemical data mining based on non-terminal vertex graph , 2004, 2004 IEEE International Conference on Systems, Man and Cybernetics (IEEE Cat. No.04CH37583).

[5]  M. Murcko,et al.  CONCERTS: dynamic connection of fragments as an approach to de novo ligand design. , 1996, Journal of medicinal chemistry.

[6]  Luhua Lai,et al.  LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design , 2000 .

[7]  Yoshimasa Takahashi,et al.  Generation of Target-Selective Drug Candidate Structures Using Molecular Evolutionary Algorithmwith SVM Classifiers , 2011 .

[8]  Amedeo Caflisch,et al.  Fragment-Based de Novo Ligand Design by Multiobjective Evolutionary Optimization , 2008, J. Chem. Inf. Model..

[9]  H. M. Vinkers,et al.  SYNOPSIS: SYNthesize and OPtimize System in Silico. , 2003, Journal of medicinal chemistry.

[10]  Regine Bohacek,et al.  Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of a de Novo Design Method Incorporating Combinatorial Growth , 1994 .

[11]  Luhua Lai,et al.  LigBuilder 2: A Practical de Novo Drug Design Approach , 2011, J. Chem. Inf. Model..

[12]  Carlo Cavazzoni,et al.  LiGen: A High Performance Workflow for Chemistry Driven de Novo Design , 2013, J. Chem. Inf. Model..

[13]  Gisbert Schneider,et al.  Flux (2): Comparison of Molecular Mutation and Crossover Operators for Ligand-Based de Novo Design , 2007, J. Chem. Inf. Model..

[14]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[15]  M Karplus,et al.  HOOK: A program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site , 1994, Proteins.

[16]  C. Fotsch,et al.  Mitigating heterocycle metabolism in drug discovery. , 2012, Journal of medicinal chemistry.

[17]  Yoshimasa Takahashi,et al.  Predictive Activity Profiling of Drugs by Topological-Fragment-Spectra-Based Support Vector Machines , 2008, J. Chem. Inf. Model..

[18]  Julen Oyarzabal,et al.  Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists. , 2009, Journal of medicinal chemistry.

[19]  G. Labesse,et al.  LEA3D: a computer-aided ligand design for structure-based drug design. , 2005, Journal of medicinal chemistry.

[20]  Gisbert Schneider,et al.  Flux (1): A Virtual Synthesis Scheme for Fragment-Based de Novo Design , 2006, J. Chem. Inf. Model..

[21]  Alastair J. King,et al.  Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. , 2013, ACS medicinal chemistry letters.

[22]  Gareth Jones,et al.  Elucidating Molecular Overlays from Pairwise Alignments Using a Genetic Algorithm , 2009, J. Chem. Inf. Model..

[23]  Sheng-Yong Yang,et al.  PhDD: a new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility. , 2010, Journal of molecular graphics & modelling.

[24]  Thomas Bäck,et al.  The Molecule Evoluator. An Interactive Evolutionary Algorithm for the Design of Drug-Like Molecules , 2006, J. Chem. Inf. Model..

[25]  W Patrick Walters,et al.  What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.

[26]  Junmei Wang,et al.  Genetic Algorithm-Optimized QSPR Models for Bioavailability, Protein Binding, and Urinary Excretion , 2006, J. Chem. Inf. Model..

[27]  Brian B. Masek,et al.  NovoFLAP: A Ligand-Based De Novo Design Approach for the Generation of Medicinally Relevant Ideas , 2010, J. Chem. Inf. Model..

[28]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[29]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[30]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[31]  Petra Schneider,et al.  De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks , 2000, J. Comput. Aided Mol. Des..

[32]  Yoshimasa Takahashi,et al.  Structural Similarity Analysis Based on Topological Fragment Spectra , 1998 .

[33]  Matthew W D Perry,et al.  Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092. , 2012, Bioorganic & medicinal chemistry letters.

[34]  J. Jenkins,et al.  A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. , 2004, Journal of medicinal chemistry.

[35]  A. Waterson,et al.  Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. , 2011, Bioorganic & medicinal chemistry letters.